CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity

Lupus

Volumn 6, Issue 5, 1997, Pages 449-454

  Su, C C ^a,c   Shau, W Y ^b   Wang, C R ^a   Chuang, C Y ^a   Chen, C Y ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

CD3; CD69; SLEDAI; Systemic lupus erythematosus

Indexed keywords

CD3 ANTIGEN; CD69 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DNA ANTIBODY; DOUBLE STRANDED DNA; MARKER;

ADULT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; VARIANCE;

EID: 0030845367     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339700600507     Document Type: Article

References (18)

1. Lanier LL et al. Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 antigen. J Exp Med 1988; 167: 1572-1585.
2. Cosulich ME et al. Functional characterization of an antigen involved in an early step of T-cell activation. Proc Natl Acad Sci USA 1987; 884: 4205-4209.
3. Yesti R, Phillips JH, Lamer LL. Constitutive expression of phosphorylated activation antigen (Leu 23) by CD3 bright human thymocytes. J Immunol 1988; 141: 2557-2563.
4. Gavioli R et al. CD69 molecule in human neutrophils: its expression and role in signal-transducing mechanism. Cell Immunol 1992; 142: 186-196.
5. Nishikawa K et al. In vivo expression of CD69 on lung eosinophils in eosmophilic pneumonia: CD69 as a possible activation marker for eosinophils. J Allergy Clin Immunol 1992; 90: 169-174.
6. Lopez-Cabrera M et al. Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the c-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 1993; 178: 537-547.
7. Ziegler SG et al. The mouse CD69 gene, structure, expression, and mapping to the NK gene complex. J Immunol 1994; 152: 1228-1236.
8. Testi R, Phillips JH, Lanier LL. T cell activation via Leu-23 (CD69). J Immunol 1989; 143: 1123-1128.
9. Sanchez-Mateos P, Sanchez-Madrid F. Structure function relationship and immunochemical mapping of external and intracellular antigenic sites on the lymphocyte activation inducer molecule, AIM/CD69. Eur J Immunol 1991; 21: 2317-2325.
10. Sakane T et al. B cell hyperactivity and its relation to distinct clinical features and the degree of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1988; 31: 80-87.
11. Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1272-1277.
12. Bombardier C et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
13. Schur PH, Sandson J. Immunological factors and clinical activity in lupus erythematosus. N Engl J Med 1968; 278: 533-538.
14. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic feature. Am J Med 1979; 66: 210-215.
15. Bluestein H. Neuropsychiatric disorders of SLE. In: Lahita RD (ed). Systemic Lupus Erythematosus. 2 edn. New York, John Wiley & Sons, 1992; pp 639-656.
16. Al-Janadi M, Raziuddin S. B cell hyperactivity is a function of T-cell-derived cytokines in systemic lupus erythematosus. J Rheumatol 1993; 20: 1888-1891.
17. Spronk PE, Gun BT, Limburg PC, Kallenberg CG. B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti-ds DNA, not to concurrent T cell activation. Clin Exp Immunol 1993; 93: 39-44.
18. Swaak AJ et al. Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocyte count and disease course. Clin Rheumatol 1995; 14: 293-300.